SUSPENSION LETTER - MAILED
mailed
on 23 Sep 2024
Last Applicant/ Owned by
75 Hayden Avenue
Lexington
MA
02421
Serial Number
98140452 filed on 18th Aug 2023
Registration Number
N/A
Correspondent Address
Keith Toms, Esq.
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
VOYAGER THERAPEUTICS
Biotechnology research services; research and development of platform technologies for delivery of therapies; research and development of platform technologies for delivery of gene therapies, antibody therapies and pharmaceuticals; research and development regarding the use of RNA-based functional screening platforms to discover, research and develop novel capsids for genetic delivery of therapies Read More
Classification Information
Class [045]
Personal & Legal & Social Services
Collaboration services in the field of platform technologies for delivery of therapies and pharmaceuticals, namely, licensing of intellectual property
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [044]
Medical, Beauty & Agricultural Services
Medical services provided for clinical trials; providing patient care for clinical trials; providing medical information in the field of gene therapy; providing a website featuring medical information; medical treatment of neurological diseases, neurodegenerative diseases, and diseases of the central nervous system, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, and Huntington's disease, and prion disease
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [042]
Computer & Software Services & Scientific Services
Biotechnology research services; research and development of platform technologies for delivery of therapies; research and development of platform technologies for delivery of gene therapies, antibody therapies and pharmaceuticals; research and development regarding the use of RNA-based functional screening platforms to discover, research and develop novel capsids for genetic delivery of therapies and pharmaceuticals; Pharmaceutical research and development in the field of gene therapy and antibody therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy and antibody therapy; pharmaceutical research services; research and development of pharmaceutical preparations for non-viral and gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development in the pharmaceutical and biotechnology fields; research and development regarding the delivery of therapies across the blood-brain barrier; research and development regarding the non-viral and viral vectors for the delivery of therapeutic agents; research and development regarding the identification and targeting of specific cells and tissues for gene therapy; providing scientific research information in the field of clinical trials; hosting a website featuring medical research information
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; antibody and gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via antibody, gene replacement, gene knockdown, or vectorized antibodies; antibody and gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; Drug delivery agents comprising capsids viral platforms, and non-viral platforms, that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; pharmaceutical for the treatment of neurodegenerative diseases and diseases of the central nervous system, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, Huntington's disease, and prion disease
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 98140452
Mark Type
No Service Mark
Attorney Docket Number
No 135333-91001
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
26.01.06 -
Semi-circles
Legal History
| Status Date | Action Taken |
|---|---|
| 23rd Sep 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| 23rd Sep 2024 | SUSPENSION LETTER WRITTEN |
| 23rd Sep 2024 | LETTER OF SUSPENSION E-MAILED |
| 20th Sep 2024 | EXAMINER'S AMENDMENT ENTERED |
| 20th Sep 2024 | ASSIGNED TO LIE |
| 19th Sep 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 19th Sep 2024 | EXAMINERS AMENDMENT E-MAILED |
| 19th Sep 2024 | EXAMINERS AMENDMENT -WRITTEN |
| 23rd Jul 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| 23rd Jul 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |